NanoLithium (low-dose lithium microemulsion) / Medesis 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NanoLithium (low-dose lithium microemulsion) / Medesis
2021-001273-23: A prospective, multicenter, with a first randomized, placebo-controlled, parallel-group, double-blind period followed by an open-label trial period to evaluate the clinical safety and efficacy of NanoLithium® NP03 in patients with moderate-to-severe Alzheimer’s disease: a proof-of-concept study

Not yet recruiting
2
68
Europe
NanoLithium® NP03, Oral emulsion
MEDESIS PHARMA SA, MEDESIS Pharma SA
Sufficient clinical and paraclinical information for the diagnosis of Alzheimer’s Disease (AD) according to the international diagnosis criteria from McKhann G. M. et al. 2011, moderate-to-severe Alzheimer’s Disease (AD), Diseases [C] - Nervous System Diseases [C10]
 
 
NanoLi®_AD, NCT05423522 / 2021-001273-23: Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

Completed
2
72
Europe
NanoLithium® NP03, Placebo
Medesis Pharma SA, MEDESIS Pharma SA
Alzheimer's Disease
01/24
10/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NanoLithium (low-dose lithium microemulsion) / Medesis
2021-001273-23: A prospective, multicenter, with a first randomized, placebo-controlled, parallel-group, double-blind period followed by an open-label trial period to evaluate the clinical safety and efficacy of NanoLithium® NP03 in patients with moderate-to-severe Alzheimer’s disease: a proof-of-concept study

Not yet recruiting
2
68
Europe
NanoLithium® NP03, Oral emulsion
MEDESIS PHARMA SA, MEDESIS Pharma SA
Sufficient clinical and paraclinical information for the diagnosis of Alzheimer’s Disease (AD) according to the international diagnosis criteria from McKhann G. M. et al. 2011, moderate-to-severe Alzheimer’s Disease (AD), Diseases [C] - Nervous System Diseases [C10]
 
 
NanoLi®_AD, NCT05423522 / 2021-001273-23: Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

Completed
2
72
Europe
NanoLithium® NP03, Placebo
Medesis Pharma SA, MEDESIS Pharma SA
Alzheimer's Disease
01/24
10/24

Download Options